

1 **Research Paper**

2 Spread of infection and treatment interruption among Japanese workers during the

3 COVID-19 pandemic: a cross-sectional study

4

5 **Running title:** Spread of infection and treatment interruption in Japan

6

7 **Author names and affiliations.**

8 Jun Akashi¹, M.D., Ayako Hino², M.D., Ph.D., Seichiro Tateishi³, M.D., Ph.D.,

9 Tomohisa Nagata⁴, M.D., Ph.D., Mayumi Tsuji⁵, M.D., Ph.D., Akira Ogami⁶, M.D.,

10 Ph.D., Shinya Matsuda⁷, M.D., Ph.D., Masaharu Kataoka¹, M.D., Ph.D., and Yoshihisa

11 Fujino⁸, M.D., M.P.H., Ph.D., for the CORoNaWork Project

12 ¹ Second Department of Internal Medicine, School of Medicine, University of

13 Occupational and Environmental Health, Japan

14 ² Department of Mental Health, Institute of Industrial Ecological Sciences, University of

15 Occupational and Environmental Health, Japan

16 ³ Department of Occupational Medicine, School of Medicine, University of

17 Occupational and Environmental Health, Japan

18 ⁴ Department of Occupational Health Practice and Management, Institute of Industrial

19 Ecological Sciences, University of Occupational and Environmental Health, Japan

20 ⁵ Department of Environmental Health, School of Medicine, University of Occupational

21 and Environmental Health, Japan

22 ⁶ Department of Work Systems and Health, Institute of Industrial Ecological Sciences,

23 University of Occupational and Environmental Health, Japan

24 ⁷ Department of Preventive Medicine and Community Health, School of Medicine,

25 University of Occupational and Environmental Health, Japan

26 ⁸ Department of Environmental Epidemiology, Institute of Industrial Ecological

27 Sciences, University of Occupational and Environmental Health, Japan

28

29 **Corresponding author, Present address**

30 Address correspondence to Yoshihisa Fujino, M.D., M.P.H., Ph.D.

31 Department of Environmental Epidemiology, Institute of Industrial Ecological Sciences,

32 University of Occupational and Environmental Health, Japan

33 1-1, Iseigaoka, Yahatanishiku, Kitakyushu, 807-8555, Japan

34 Tel: +81-93-691-7401

35

36 **Word count:**

37 Main text: 1969 words

38 Abstract: 242 words

39

40 **Abstract**

41 **Objectives:** This study aimed to examine the relationship between regional infection
42 level and treatment interruption for chronic diseases.

43 **Methods:** A cross-sectional Internet monitoring survey was performed between
44 December 22 and 26, 2020. Data from 9,510 (5,392 males and 4,118 females)
45 participants needing regular treatment or hospital visits were analyzed. We determined
46 the age-sex- and multivariate-adjusted odds ratios (ORs) of treatment interruption
47 associated with various indices of infection level by nesting multilevel logistic models
48 in prefecture of residence. In the multivariate model, sex, age, marital status, job type,
49 equivalent household income, education, self-rated health, and anxiety were adjusted.

50 **Results:** The ORs of treatment interruption for the lowest versus highest levels of
51 infection were 1.32 (95% CI: 1.09–1.59) for the overall incidence rate (per 1,000
52 population), 1.34 (95% CI: 1.10–1.63) for the overall number of people infected, 1.28
53 (95% CI: 1.06–1.54) for the monthly incidence rate (per 1,000 population), and 1.38
54 (95% CI: 1.14–1.67) for the number of people infected per month. For each index of
55 infection level, higher infection was linked to more workers experiencing treatment
56 interruption.

57 **Conclusion:** Higher local infection levels were linked to more workers experiencing
58 treatment interruption. Our results suggest that apart from individual characteristics
59 such as socioeconomic and health status, treatment interruptions during the pandemic
60 were also subject to contextual effects related to regional infection levels. Preventing
61 community spread of COVID-19 may thus protect individuals from indirect effects of
62 the pandemic, such as treatment interruption.

63

64 **Keywords:** COVID-19, Japan, Patient Acceptance of Health Care, Treatment Refusal,

65 Regional Medical Programs

66

67 **Introduction**

68 COVID-19, first identified at the end of 2019, is continuing to rage around the
69 world [1-4]. Japan has experienced four waves of the disease through June 2021. In
70 addition to direct effects of severe pneumonia and acute respiratory failure, COVID-19
71 has also had indirect health effects. COVID-19-related treatment interruption,
72 particularly in patients with chronic diseases, is an emerging issue in several countries
73 [5,6], including Japan [7]. Studies have reported a significant decrease in the number of
74 prescriptions during the pandemic compared to before, and that 40% of patients
75 requiring regular visits have been seen less frequently [8,9].

76 Treatment interruption can cause serious health care problems in several ways.
77 First, it can worsen the medical condition of patients with chronic diseases that require
78 regular management. Second, fewer opportunities for regular physical examinations
79 may lead to undiagnosed complications and delayed treatment. Further, such medical
80 problems, which could have been avoided by continued treatment, increases medical
81 costs [10]. Studies performed during the COVID-19 pandemic have reported that
82 treatment interruption among patients with chronic diseases is associated with a variety
83 of factors, including fear of becoming infected when seeing the doctor [11,12],
84 scheduling changes by hospitals [13,14], and shortage of medical resources [11]. These
85 factors presumably have differing degrees of impact depending on the level of infection
86 in the region. In addition, patients with unstable socioeconomic status are more likely to
87 discontinue treatment [7,15,16]. Areas with higher prevalence of COVID-19 may be
88 more affected by the loss of job security and other factors that affect individuals with
89 unstable socioeconomic status.

90 In Japan, the spread of COVID-19 has varied widely by region in terms of the
91 scale of infection and the speed of spread [17,18]. We hypothesize that differences in
92 regional infection rates will affect treatment interruption in each region. The level of
93 infection in a community may directly or indirectly affect fear of visiting medical
94 institutions, anxiety about going out, and financial difficulties, which may cause
95 treatment interruption. For example, the number of people infected with COVID-19 is
96 reported daily by region. Such information will arouse some degree of anxiety and fear
97 in people living in regions with high levels of infection about the safety of the area and
98 the disease. Tokyo, which has recorded the greatest number of infections in Japan, saw
99 a significant drop in prescriptions through May 2020 [8]. Given that pandemics are
100 known to overwhelm medical resources [19], Japan's lack of capacity to conduct
101 COVID-19 tests in areas with high levels of infection and limited hospital beds has
102 exposed the limits of the country's medical resources [20].

103 However, the relationship between regional COVID-19 infection level and
104 treatment interruption remains to be elucidated. Japan provides an ideal opportunity to
105 test our hypotheses due to the country's large regional variation in COVID-19 infection
106 levels. Therefore, we investigated the relationship between local infection level and
107 treatment interruption in Japan.

108

109 **Materials and Methods**

110 **Study Design and Subjects**

111 A cross-sectional study of Internet monitors was conducted from December 22
112 to 26, 2020, the period corresponding to Japan's third wave of infection. Data were
113 obtained from participants who indicated they were employed at the time of the survey,
114 with participants selected based prefecture of residence, job type, and sex. A detailed
115 description of the protocol of this survey is provided elsewhere [21]. Of the 33,302
116 participants in the survey, 6,266 were excluded for providing fraudulent responses. Of
117 the 27,036 remaining participants, data from 9,510 (5392 males and 4118 females) who
118 stated they needed regular treatment or hospital visits were analyzed.

119 This study was approved by the Ethics Committee of the University of
120 Occupational and Environmental Health, Japan (reference No. R2-079 and R3-006).
121 Participants provided informed consent by completing a form on the survey website.

122

123 **Treatment status**

124 We used a single-item question to assess participants' treatment status: "Do you
125 have a condition that requires regular hospital visits or treatment?" Participants chose
126 from "I do not have such a condition," "I am continuing with hospital visits and
127 treatment as scheduled," and "I am not able to continue with hospital visits and
128 treatment as scheduled."

129

130 **Infection level indices**

131 The infection level in each participant’s prefecture of residence was assessed
132 based on the incidence rate for the entire period (per 1,000 population), the number of
133 people infected for the entire period, the incidence rate in one month (per 1,000
134 population), and the number of infected people in one month.

135

136 **Socioeconomic status, health status, and anxiety**

137 Socioeconomic status, health status, and anxiety were assessed through
138 questionnaires in the Internet survey. Socioeconomic factors were age, sex, marital
139 status (married, unmarried, bereaved/divorced), occupation (mainly desk work, mainly
140 interpersonal communication, mainly labor), education, and equivalent income
141 (household income divided by the square root of household size). Health and
142 psychological factors were assessed through participants’ self-rated health status and
143 anxiety about contracting COVID-19. We used the following question to assess anxiety:
144 “Do you feel anxious about being infected with COVID-19?” Participants chose from
145 “yes” or “no.”

146

147 **Statistical analysis**

148 We estimated age-sex- and multivariate-adjusted odds ratios (ORs) of
149 treatment interruption associated with regional infection level by nesting multilevel
150 logistic models in prefecture of residence. We used four indices of regional infection
151 level: incidence rate for the entire period (per 1,000 population), number of people
152 infected for the entire period, incidence rate in one month (per 1,000 population), and
153 number of people infected in one month. For analysis, these indices were divided into

154 quartiles and used as area-level variables. In the multivariate model, sex, age, marital
155 status, job type, equivalent household income, education, self-rated health, and anxiety
156 were adjusted. $p < 0.05$ indicated statistical significance. All analyses were conducted
157 using Stata (Stata Statistical Software: Release 16; StataCorp LLC, TX, USA).
158

159 **Results**

160 The participants' characteristics together with residential area according to the
161 number of people infected for the entire period are summarized in Table 1. We stratified
162 the 9,510 participants in need of regular treatment into four groups according to the
163 regional infection level. Socioeconomic factors including sex, age, marital status,
164 household income, education, and occupation, and self-assessment of health status and
165 anxiety related to COVID-19 infection were similar among the four groups.

166 The association between the regional infection level and treatment interruption is
167 summarized in Table 2. According to multivariate analysis, the ORs of treatment
168 interruption for the lowest versus highest regional infection level were 1.32 (95% CI:
169 1.09–1.59; $p=0.003$) for the overall incidence rate (per 1,000 population), 1.34 (95% CI:
170 1.10–1.63; $p=0.002$) for the overall number of people infected, 1.28 (95% CI:
171 1.06–1.54; $p=0.013$) for the monthly incidence rate (per 1,000 population), and 1.38
172 (95% CI: 1.14–1.67; $p=0.001$) for the number of people infected per month. For each
173 index of infection level, a higher infection level was linked to more workers
174 experiencing treatment interruption for chronic diseases in Japan. The results remained
175 unchanged after adjusting for age and sex.

176

177 **Discussion**

178 We found that higher regional levels of COVID-19 infection in Japan were
179 correlated with more workers with diseases requiring regular hospital visits and
180 treatment experiencing treatment interruption. To our knowledge, this is the first report
181 to show that community infection levels are associated with treatment interruption.

182 It is important to emphasize that the association between infection level and
183 treatment interruption remained after adjusting for individual factors such as
184 socioeconomic and health status. These results suggest that apart from individual
185 characteristics, treatment interruptions during the COVID-19 pandemic were also
186 subject to contextual effects related to regional infection levels. For example, while
187 anxiety related to fear of becoming infected during a medical visit is a personal reaction,
188 individuals living in areas with high levels of infection are likely to feel more anxious
189 than those living in areas with low levels of infection. Rescheduling by medical
190 institutions and health care providers is also expected to occur in areas with higher
191 infection levels. Additionally, the COVID-19 pandemic is affecting individuals'
192 socioeconomic status, which is determined by factors such as employment instability.
193 Higher levels of infection have greater socioeconomic impact, which may be a factor
194 affecting treatment interruption. Our findings are consistent with those of a previous
195 study showing that such individual factors influence treatment interruption [7]. Thus,
196 our study demonstrates that local spread of COVID-19 infection may affect the
197 behavioral characteristics of workers living in the area. These findings suggest that, in
198 addition to an individual patient approach, a population strategy is also needed to
199 prevent the spread of infection and to avoid treatment interruption for manageable
200 diseases.

201 In this study, both the number of infected people by region and infection rate
202 were associated with treatment interruption. This suggests that it would be informative
203 to report the incidence rate based on the infection status in each region, which reflects
204 the population of that region. However, Japanese news reports tend to emphasize the
205 number of infected people rather than the infection rate by region, the latter of which
206 may contribute to changing the behavior of more people. A previous study reported that
207 Japanese people have greater trust in local information [22], suggesting that reporting
208 the number of infections by region will have a strong influence on individual's
209 behavioral changes and risk perception.

210 Increased treatment interruption in areas with high levels of infection may cause
211 further strain on future health care resources. Delaying and avoiding treatment can
212 result in poorer management of chronic diseases, fewer regular checkups, and missed or
213 delayed start of therapy for deteriorating health conditions. It can also lead to increased
214 complications and poor prognosis. These factors in turn can increase future health care
215 needs in the region. The strain on local health care resources due to the COVID-19
216 pandemic is a serious challenge, and treatment interruption may be an indirect burden
217 on health care resources due to COVID-19. Thus, reducing treatment interruption for
218 manageable diseases may alleviate downstream consequences on the health care system.

219 The findings of this study indicate that controlling the level of infection in a
220 community has important implications for treatment interruption. With the COVID-19
221 pandemic expected to continue for some time, sustained control of community-level
222 spread will protect populations from the indirect effects of COVID-19, which include
223 treatment interruption. In addition, strategies are needed to prevent treatment
224 interruption. For example, telemedicine has and will continue to play a major role in the

225 provision of health care during the COVID-19 pandemic [23-26]. Furthermore,
226 educating patients to avoid treatment interruption and widespread use of long-term
227 prescriptions to prevent patients from running out of regular medications will help
228 reduce medical problems caused by treatment interruption.

229 A major strength of this study was the relatively large sample size, which
230 allowed us to show, for the first time, an association between community infection level
231 and treatment interruption.

232 However, this study also had several limitations. First, because we conducted a
233 cross-sectional study, causality could not be determined. However, since it is
234 theoretically unlikely that treatment interruption experienced by an individual will
235 increase the COVID-19 infection rate in a region, we think it is likely that high regional
236 infection rates cause treatment interruption. Second, we did not identify workers'
237 reasons for discontinuing treatment in this study. As discussed above, there are various
238 possible causes of treatment interruption, which may vary by region. Third, we did not
239 inquire about the diseases being treated. Treatment interruption may vary depending on
240 the presence or absence of symptoms and the potential disadvantages of discontinuing
241 treatment for a particular disease.

242

243 **Conclusion**

244 We found that higher regional infection levels were linked to more workers
245 experiencing treatment interruption during the third wave of COVID-19 infection in
246 Japan. Our findings suggest that in addition to individual factors such as socioeconomic
247 status and health status, high regional infection levels may contribute to behavioral
248 changes in the local population, leading to treatment interruption. Preventing
249 community spread of COVID-19 may thus be useful for avoiding treatment interruption
250 for chronic diseases, an emerging medical problem brought about by COVID-19.

251

252 **Funding**

253 This study was supported and partly funded by the University of Occupational
254 and Environmental Health, Japan; General Incorporated Foundation (Anshin Zaidan);
255 The Development of Educational Materials on Mental Health Measures for Managers at
256 Small-sized Enterprises; Health, Labour and Welfare Sciences Research Grants;
257 Comprehensive Research for Women's Healthcare (H30-josei-ippan-002); Research for
258 the Establishment of an Occupational Health System in Times of Disaster
259 (H30-roudou-ippan-007), scholarship donations from Chugai Pharmaceutical Co., Ltd.,
260 the Collabo-Health Study Group, and Hitachi Systems, Ltd.

261

262 **Data statement**

263 Data not available due to ethical restrictions.

264

265 **Conflict of interest:**

266 The authors declare no conflicts of interest associated with this manuscript.

267

268 **Acknowledgements**

269 The current members of the CORoNaWork Project, in alphabetical order, are as
270 follows: Dr. Yoshihisa Fujino (present chairperson of the study group), Dr. Akira
271 Ogami, Dr. Arisa Harada, Dr. Ayako Hino, Dr. Hajime Ando, Dr. Hisashi Eguchi, Dr.
272 Kazunori Ikegami, Dr. Kei Tokutsu, Dr. Keiji Muramatsu, Dr. Koji Mori, Dr. Kosuke
273 Mafune, Dr. Kyoko Kitagawa, Dr. Masako Nagata, Dr. Mayumi Tsuji, Ms. Ning Liu,
274 Dr. Rie Tanaka, Dr. Ryutaro Matsugaki, Dr. Seiichiro Tateishi, Dr. Shinya Matsuda, Dr.
275 Tomohiro Ishimaru, and Dr. Tomohisa Nagata. All members are affiliated with the
276 University of Occupational and Environmental Health, Japan.

277

278 **References**

- 279 1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical
280 Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med.*
281 2020;382(18):1708-20.
- 282 2. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First
283 Case of 2019 Novel Coronavirus in the United States. *N Engl J Med.*
284 2020;382(10):929-36.
- 285 3. Phan LT, Nguyen TV, Luong QC, Nguyen TV, Nguyen HT, Le HQ, et al.
286 Importation and Human-to-Human Transmission of a Novel Coronavirus in
287 Vietnam. *N Engl J Med.* 2020;382(9):872-4.
- 288 4. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al.
289 Transmission of 2019-nCoV Infection from an Asymptomatic Contact in
290 Germany. *N Engl J Med.* 2020;382(10):970-1.
- 291 5. Birkmeyer JD, Barnato A, Birkmeyer N, Bessler R, Skinner J. The Impact
292 Of The COVID-19 Pandemic On Hospital Admissions In The United States.
293 *Health Aff.* 2020;39(11):2010–2017.
- 294 6. Czeisler M, Marynak K, Clarke KEN, Salah Z, Shakya I, Thierry JM, et al.
295 Delay or Avoidance of Medical Care Because of COVID-19-Related Concerns -
296 United States, June 2020. *MMWR Morb Mortal Wkly Rep.*
297 2020;69(36):1250-7.
- 298 7. Fujimoto K, Ishimaru T, Tateishi S, Nagata T, Tsuji M, Eguchi H, et al. A
299 cross-sectional study of socioeconomic status and treatment interruption among
300 Japanese workers during the COVID-19 pandemic. *medRxiv.*
301 2021:2021.02.22.21252190.

- 302 8. LoPresti M, Seo T, Sato N. Pandemics and Access to Care: Use of
303 Real-World DATA to Examine the IMPACT of COVID-19 on Pharmacy Visits
304 in JAPAN. *Value Health*. 2020;23:S685.
- 305 9. Takakubo T, Odagiri Y, Machida M, Takamiya T, Fukushima N, Kikuchi H, et
306 al. Changes in the medical treatment status of Japanese outpatients during the
307 coronavirus disease 2019 pandemic. *Journal of General and Family Medicine*.
308 2021;00:1–16.
- 309 10. Erol MK, Kayıkçıoğlu M, Kılıçkap M, Güler A, Yıldırım A, Kahraman F, et al.
310 Treatment delays and in-hospital outcomes in acute myocardial infarction during
311 the COVID-19 pandemic: A nationwide study. *Anatol J Cardiol*.
312 2020;24(5):334-42.
- 313 11. Czeisler M, Marynak K, Clarke KEN, Salah Z, Shakya I, Thierry JM, et al.
314 Delay or Avoidance of Medical Care Because of COVID-19-Related Concerns -
315 United States, June 2020. *MMWR Morb Mortal Wkly Rep*.
316 2020;69(36):1250-7.
- 317 12. Chudasama YV, Gillies CL, Zaccardi F, Coles B, Davies MJ, Seidu S, et al.
318 Impact of COVID-19 on routine care for chronic diseases: A global survey of
319 views from healthcare professionals. *Diabetes Metab Syndr*. 2020;14(5):965-7.
- 320 13. Chopra V, Toner E, Waldhorn R, Washer L. How Should U.S. Hospitals Prepare
321 for Coronavirus Disease 2019 (COVID-19)? *Ann Intern Med*.
322 2020;172(9):621-2.
- 323 14. Khullar D, Bond AM, Schpero WL. COVID-19 and the Financial Health of
324 US Hospitals. *JAMA*. 2020;323(21):2127–2128.

- 325 15. Feinstein JS. The relationship between socioeconomic status and health: a
326 review of the literature. *Milbank Q.* 1993;71(2):279-322.
- 327 16. Swain GR. How does economic and social disadvantage affect health. *Focus.*
328 2016;33(1):1-6.
- 329 17. Ministry of Health, Labour and Welfare. Current status of the novel co-
330 ronavirus infection and the response of the MHLW. 31 December 2020.
331 Available at: https://www.mhlw.go.jp/stf/newpage_15828.html. Accessed June
332 27, 2021.
- 333 18. Furuse Y, Ko YK, Saito M, Shobugawa Y, Jindai K, Saito T, et al.
334 Epidemiology of COVID-19 Outbreak in Japan, from January-March 2020. *Jpn*
335 *J Infect Dis.* 2020;73(5):391-3.
- 336 19. Emanuel EJ, Persad G, Upshur R, Thome B, Parker M, Glickman A, et al. Fair
337 Allocation of Scarce Medical Resources in the Time of Covid-19. *N Engl J Med.*
338 2020;382(21):2049-55.
- 339 20. Watanabe M. The COVID-19 Pandemic in Japan. *Surg Today.*
340 2020;50(8):787-93.
- 341 21. Fujino Y, Ishimaru T, Eguchi H, et al. Protocol for a nationwide
342 Internet-based health survey in workers during the COVID-19 pandemic in 2020.
343 medRxiv. Published online February 5, 2021:2021.02.02.21249309.
- 344 22. Muto K, Yamamoto I, Nagasu M, Tanaka M, Wada K. Japanese citizens'
345 behavioral changes and preparedness against COVID-19: An online survey
346 during the early phase of the pandemic. *PLoS One.* 2020;15(6):e0234292.

- 347 23. Grabowski DC, O'Malley AJ. Use of telemedicine can reduce hospitalizations of
348 nursing home residents and generate savings for medicare. *Health Aff*
349 (Millwood). 2014;33(2):244-50.
- 350 24. Bokolo Anthony J. Use of Telemedicine and Virtual Care for Remote Treatment
351 in Response to COVID-19 Pandemic. *J Med Syst*. 2020;44(7):132.
- 352 25. Neubeck L, Hansen T, Jaarsma T, Klompstra L, Gallagher R. Delivering
353 healthcare remotely to cardiovascular patients during COVID-19: A rapid
354 review of the evidence. *Eur J Cardiovasc Nurs*. 2020;19(6):486-94.
- 355 26. Elson EC, Oermann C, Duehlmeyer S, Bledsoe S. Use of telemedicine to
356 provide clinical pharmacy services during the SARS-CoV-2 pandemic. *Am J*
357 *Health Syst Pharm*. 2020;77(13):1005-6.
- 358

Table 1. Basic characteristics of the study subjects

	Residential area according to the number of infected people for the entire period			
	74-492	507-1496	1673-11982	12381-52382
Number of subjects	2130	2579	2422	2379
Age, median (IQR)	51 (42, 57)	51 (43, 57)	52 (44, 58)	53 (46, 58)
Sex, male	1181 (55.4%)	1440 (55.8%)	1403 (57.9%)	1368 (57.5%)
Marital status, married	1252 (58.8%)	1496 (58.0%)	1370 (56.6%)	1284 (54.0%)
Annual equivalent house hold income (JPY)				
500000-2650000	773 (36.3%)	875 (33.9%)	816 (33.7%)	717 (30.1%)
2650000-4500000	690 (32.4%)	824 (32.0%)	733 (30.3%)	648 (27.2%)
>4500000	667 (31.3%)	880 (34.1%)	873 (36.0%)	1014 (42.6%)
Education				
Junior high school	26 (1.2%)	32 (1.2%)	30 (1.2%)	36 (1.5%)
High School	703 (33.0%)	750 (29.1%)	619 (25.6%)	500 (21.0%)
Vocational school/college,university,graduate school	1401 (65.8%)	1797 (69.7%)	1773 (73.2%)	1843 (77.5%)
Jobtype				
Mainly desk work	1144 (53.7%)	1293 (50.1%)	1222 (50.5%)	1264 (53.1%)
Jobs mainly involving interpersonal communication	480 (22.5%)	590 (22.9%)	622 (25.7%)	614 (25.8%)
Mainly labor	506 (23.8%)	696 (27.0%)	578 (23.9%)	501 (21.1%)
Self-rated health				
Very good	742 (34.8%)	895 (34.7%)	895 (37.0%)	885 (37.2%)
Neither	919 (43.1%)	1104 (42.8%)	991 (40.9%)	986 (41.4%)
Not good	469 (22.0%)	580 (22.5%)	536 (22.1%)	508 (21.4%)
Do you feel anxious about being infected with COVID-19?				
Yes	1684 (79.1%)	2083 (80.8%)	1904 (78.6%)	1850 (77.8%)
The incidence rate for the entire period (per 1000 of the population), median (IQR)	.28 (.22, .34)	.55 (.51, .59)	1.26 (.79, 1.51)	3.12 (1.91, 3.76)
The number of infected people for the entire period, median (IQR)	379 (330, 445)	1053 (671, 1124)	2455 (2168, 8438)	27500 (14427, 52382)
The incidence rate for one month (per 1000 of the population), median (IQR)	.09 (.058, .14)	.23 (.16, .32)	.47 (.33, .59)	1.06 (.74, 1.06)
The number of infected people for one month, median (IQR)	124 (39, 171)	440 (282, 501)	1705 (916, 2936)	9851 (5596, 14690)

Table 2. Association between regional COVID-19 infection levels and treatment interruption

	Age-sex adjusted			Multivariate*				
	OR	95%CI	p	OR	95%CI	p		
The incidence rate for the entire period (per1000)								
.10 - .44	reference			reference				
.49 - .68	1.00	0.83	1.21	0.999	1.00	0.83	1.21	0.993
.76 - 1.63	1.06	0.88	1.28	0.555	1.07	0.88	1.30	0.505
1.89 - 3.76	1.25	1.04	1.50	0.019	1.32	1.09	1.59	0.005
				0.013†				0.003†
The number of infected people for the entire period								
74 - 492	reference			reference				
507 - 1496	1.07	0.89	1.29	0.473	1.06	0.87	1.29	0.545
1673 - 11982	1.14	0.94	1.38	0.180	1.15	0.94	1.40	0.168
12381 - 52382	1.28	1.06	1.55	0.011	1.34	1.10	1.63	0.003
				0.008†				0.002†
The incidence rate for one month (per1000)								
.018 - .15	reference			reference				
.16 - .32	1.07	0.89	1.29	0.487	1.07	0.89	1.30	0.470
.33 - .61	1.05	0.87	1.27	0.641	1.06	0.87	1.29	0.576
.66 - 1.12	1.21	1.02	1.45	0.032	1.28	1.06	1.54	0.009
				0.044†				0.013†
The number of infected people for one month								
13 - 203	reference			reference				
204 - 626	1.11	0.92	1.34	0.284	1.12	0.93	1.36	0.241
704 - 4373	1.16	0.96	1.40	0.127	1.18	0.97	1.43	0.093
5218 - 14690	1.30	1.08	1.57	0.006	1.38	1.14	1.67	0.001
				0.006†				0.001†

* The multivariate model was adjusted for age, sex, marital status, equivalent household income, educational level, jobtype, self-rated health and anxiety about infection

† p for trend